false
0001175151
0001175151
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 12, 2026
Cytosorbents Corporation
(Exact name of registrant as specified in
its charter)
| Delaware |
|
001-36792 |
|
98-0373793 |
(State or other
jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
305
College Road East
Princeton, New Jersey |
|
08540 |
| (Address of principal executive offices) |
|
(Zip code) |
Registrant’s telephone number, including
area code (973) 329-8885
| Not Applicable |
| (Former Name or Former Address, if Changed Since Last Report) |
Securities registered pursuant to Section 12(b)
of the Securities Exchange Act of 1934:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, $0.001 par value |
CTSO |
The NASDAQ Stock Market LLC
(Nasdaq Capital Market) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| |
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory Note
This Amendment No. 1
on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K filed with the Securities and Exchange Commission
on November 12, 2026 (the “Original 8-K”) by CytoSorbents Corporation (the “Company”). The Company is filing
this Amendment solely to correct certain financial information contained in the press release issued by the Company on November 12,
2026, announcing, among other things, its financial results for the quarter ended September 30, 2026 (the “Original Press Release”),
which was furnished as Exhibit 99.1 to the Original 8-K.
The Company is furnishing
a revised press release, dated November 19, 2026 (the “Revised Press Release”), to correct immaterial errors in the foreign
currency transaction loss previously recognized and related amounts, certain balance sheet and stockholders’ equity (deficit) amounts,
selling, general and administrative expenses and restructuring expenses for the nine months ended September 30, 2026, and certain
revenue growth and sales mix percentages, to conform to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30,
2026.
The Revised Press Release
is furnished with this Amendment as Exhibit 99.1 and supersedes and replaces the Original Press Release furnished as Exhibit 99.1
to the Original 8-K.
Item 2.02. Results of Operations and Financial Condition.
On November 12, 2026,
the Company issued the Original Press Release announcing its financial results for the quarter ended September 30, 2026. As described
in the Explanatory Note above, the Company is furnishing the Revised Press Release as Exhibit 99.1 to this Amendment.*
Item 7.01. Regulation FD Disclosure.
For the benefit of its investors,
the Company is furnishing an updated investor presentation in connection with its earnings conference call. A copy of the updated investor
presentation is being furnished as Exhibit 99.2.*
Item 9.01 Exhibits
(d) Exhibits
Exhibit
No. |
Description |
| 99.1 |
Revised Press Release of the Company, dated November 19, 2026 |
| 99.2 |
Revised Investor Presentation |
| 104 |
Cover Page Interactive Data File (embedded with the Inline XBRL document) |
* The information in Items 2.02 and 7.01 of this
Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in
such a filing.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Dated: November 19, 2026 |
CYTOSORBENTS CORPORATION |
| |
|
|
| |
By: |
/s/ Dr. Phillip P. Chan |
| |
Name: |
Dr. Phillip P. Chan |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
CytoSorbents
Reports Third Quarter 2026 Financial Results, Achieves
Operating Cash Flow Breakeven, and Provides Business and
Regulatory Update
Delivering on the First of Four Distinct
Value Drivers
PRINCETON,
N.J., November 12, 2026, as updated on November 19, 2026 (see Explanatory Note) — CytoSorbents Corporation
(NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification,
today reported financial results for the third quarter ended September 30, 2026, recent business highlights, and provides a regulatory
update.
Third Quarter 2026 Financial Results
| · | Revenue was $9.7 million, an increase of 3% compared to $9.5 million in Q3 2025. Growth was led by an
18% increase in distributor and strategic partner sales. |
| · | Gross margin improved to 75% in the quarter, up from 73% in Q2 2026 and 70% a year ago. |
| · | Total operating expenses decreased 11% to $8.5 million from $9.5 million in Q3 2025. Excluding $0.25 million
of restructuring charges, operating expenses decreased 13%. |
| · | Operating loss improved by 59% to $1.2 million versus $2.9 million in Q3 2025. |
| · | Net loss improved by 35% to $2.1 million or $0.65 per share, compared to a net loss of $3.2 million or
$1.01 per share in Q3 2025. All per share amounts reflect the 1-for-20 reverse stock split effected on September 8, 2026. |
| · | Adjusted net loss, which excludes the impact of non-cash changes in foreign currency transactions, non-cash
stock compensation, and restructuring charges, improved by 42% to $1.5 million or $0.48 per share, compared to an adjusted net loss of
$2.6 million or $0.83 per share in Q3 2025. |
| · | Adjusted EBITDA loss, which excludes interest payments, depreciation, taxes, and amortization, as well
as the impact of non-cash changes in foreign currency transactions, non-cash stock compensation, and restructuring charges, improved by
86% to $0.3 million compared to a loss of $2.0 million in Q3 2025. |
| · | Total cash, cash equivalents, and restricted cash was approximately $5.7 million on September 30,
2026, compared to $5.9 million at June 30, 2026. |
| · | Importantly, the Company generated positive operating cash flow of approximately $43,000 in the quarter,
excluding approximately $251,000 in restructuring-related payments, achieving its objective of operating cash flow breakeven in the second
half of 2026. Total cash burn in the quarter, inclusive of restructuring-related payments, was approximately $200,000. |
Nine Months Ended September 30, 2026 Financial
Results
| · | Revenue was $28.2 million compared to $27.8 million in the first nine months of 2025. |
| · | Gross margin improved to 73% compared to 71% in the prior year period. |
| · | Total operating expenses decreased 9% to $27.4 million, and operating loss improved by 34% to $6.9 million
from $10.4 million. |
| · | Net loss was $12.0 million or $3.82 per share, compared to $2.7 million or $0.87 per share in the prior
year period, with the change due primarily to a $2.5 million non-cash foreign currency loss in 2026 versus a $9.1 million non-cash foreign
currency gain in 2025. |
| · | Adjusted EBITDA loss improved by 45% to $4.0 million compared to a loss of $7.3 million in the prior year
period. |
“The third quarter marked an important financial
milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments,”
stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. “This achievement reflects a year of disciplined execution
and meaningful improvements in our underlying business. Product gross margin expanded to 75%, operating expenses declined 11%, operating
loss improved 59%, and notably, adjusted EBITDA loss narrowed 86% to approximately $0.3 million. These results demonstrate the impact
of our more efficient cost structure and position us to benefit from improved operating leverage as revenue grows. Importantly, every
dollar of operating cash burn we eliminate helps reduce our future financing needs and positions us to capture more of the potential value
of future growth for our shareholders.
Progress on Our Four Distinct Value Drivers
“We continue to advance four distinct value
drivers, each with the potential to create meaningful shareholder value. These include achieving sustainable operating cash flow breakeven,
restoring profitable growth in our core CytoSorb business, opening the U.S. market through DrugSorb-ATR, and unlocking the strategic value
of HemoDefend-BGA. With our first milestone achieved, we are focused on sustaining this progress while advancing the remaining three opportunities.
First
Value Driver: Achieving Operating Cash Flow Breakeven — Achieved in Q3 2026
“In the third quarter, we generated approximately
$43,000 in positive operating cash flow, excluding $251,000 in restructuring-related payments, compared with operating cash burn of approximately
$200,000 in Q2 2026 on the same basis and $2.7 million in Q3 2025.
“This improvement reflects a broad-based
effort to optimize our operations. Manufacturing efficiencies and improved sourcing helped expand product gross margin to 75%, while a
24% reduction in headcount since September 2025 and disciplined expense management significantly lowered our cost structure. We also
improved working capital management, reducing inventory from $5.3 million at year-end 2025 to $3.2 million at September 30, 2026.
“Our focus now turns to sustaining operating
cash flow at or near breakeven while selectively investing to accelerate sales growth, which has historically been constrained by limited
resources. With a significantly leaner cost structure and healthy gross margins, we believe we are now better positioned to capitalize
on growth opportunities and generate meaningful operating leverage as revenues increase. Although quarterly cash flow may fluctuate with
the timing of revenue, collections, and working capital, our goal is to maintain financial discipline while translating incremental sales
growth into improved profitability and long-term shareholder value.”
Second Value Driver: Returning CytoSorb to
Sustainable, Profitable Growth
“Our second value driver is restoring consistent,
profitable growth in our core CytoSorb franchise. Encouragingly, distributor and strategic partner sales grew 18% year-over-year and 10%
sequentially in the third quarter, while direct sales outside Germany increased 5% year-over-year. Together, these markets accounted for
77% of quarterly sales, demonstrating continued momentum across the majority of our business.
“These gains were offset by a 21% year-over-year
sales decline in Germany, which represented 23% of quarterly sales, primarily reflecting a smaller, more focused sales force and reduced
territory coverage following our commercial restructuring. Restoring growth in Germany is a top priority and an important opportunity
to accelerate overall revenue growth. To address this, we have already added two sales representatives, expect another next month, and
add two more through early 2027.
We also recently welcomed Alex Tiefenbacher as
Senior Vice President of Direct Sales, bringing extensive acute and critical care medical device sales leadership experience from C.R.
Bard, Becton Dickinson, GE Healthcare, and Baxter. Alex will lead our direct sales organization in Germany and internationally, working
closely with our sales leaders in those two verticals, with an initial focus on revitalizing the German market and building a scalable
platform for sustained growth. We believe these targeted investments in commercial leadership and sales capacity will strengthen execution,
expand territory coverage, deepen customer relationships, and position us to return to growth as new representatives become productive.
“Meanwhile, our 'Right Patient, at the Right
Time, with the Right Dose' commercial strategy continues to gain traction, supported by our PuriFi® pump platform and HotSwap®
technology, which simplify treatment delivery and enable earlier, more consistent CytoSorb use. We are also strengthening our clinical
evidence base, including new data presented at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting highlighting
applications in blood thinner removal, post-operative shock, VA-ECMO support, and heart transplantation, as well as findings from the
international COSMOS critical care registry presented at the European Society of Intensive Care Medicine (ESICM) LIVES 2026 congress addressing
sepsis, liver support, and VV-ECMO.
“We believe a combination of renewed growth
in Germany, sustained international momentum, an expanding clinical evidence base, and a leaner cost structure positions our core CytoSorb
franchise to accelerate revenue growth, leverage our attractive gross margins, and translate increasing sales into meaningful improvements
in profitability and cash flow.
Third
Value Driver: Opening the U.S. Market Through DrugSorb-ATR
“Our third value driver is to obtain FDA
marketing authorization for DrugSorb-ATR, potentially opening a second major engine for growth. DrugSorb-ATR is designed to remove commonly
prescribed blood thinners during cardiopulmonary bypass in patients requiring urgent cardiac surgery, with the goal of reducing serious
and life-threatening bleeding complications. Subject to regulatory authorization, we estimate an initial addressable market of approximately
$300 million in the United States and Canada, that we estimate could expand to $1-2 billion with label expansion to other blood thinners
and additional surgical indications.
“During the quarter, we made meaningful
progress on our new intended De Novo submission to FDA on DrugSorb-ATR. At the European Society of Cardiology congress this past August,
an independent patient-matched analysis evaluated 587 patients undergoing urgent coronary artery bypass grafting (CABG) surgery following
recent exposure to Brilinta® (ticagrelor). The analysis demonstrated a statistically significant 37% relative reduction in severe
BARC-4 bleeding with intraoperative CytoSorb use (21.8% versus 34.5% control; p=0.002), resulting in a clinically impactful NNT (Number
Needed to Treat) of approximately eight patients to prevent one severe bleeding event. Significant reductions in chest tube drainage and
red blood cell transfusions were also observed, with no serious device-related adverse events.
“This analysis of real-world data is particularly
important because it was previously proposed by the FDA during the appeal of our original De Novo submission and is expected to be a key
component of our planned new De Novo submission in early 2027. We expect this additional evidence to increase approximately fivefold the
number of patients treated with our technology represented in the submission, to approximately 250 patients. Meanwhile, based on a constructive
FDA pre-submission meeting in August, we are working to finalize an animal study protocol with the FDA to collect additional mechanistic
data. Taken together with STAR-T data, and previously submitted safety data, we believe this real-world analysis and mechanistic data
will provide a substantially expanded body of evidence supporting the clinical benefit of DrugSorb-ATR for FDA review.
“In parallel, in a separate FDA pre-submission
meeting, we advanced discussions with the Agency regarding the data requirements of a separate De Novo submission expected next year for
the removal of direct oral anticoagulants, including Eliquis® (apixaban) and Xarelto® (rivaroxaban), during urgent cardiac surgery,
which could significantly expand the addressable U.S. market for our technology given the widespread use of these medications.
“Importantly, the Brilinta® and direct
oral anticoagulant programs offer two distinct potential pathways to U.S. commercialization, each supported by its own clinical evidence
and regulatory strategy.
Fourth Value Driver: Unlocking the Strategic
Value of HemoDefend-BGA
“Our fourth value driver is realizing the
strategic value of HemoDefend-BGA, a differentiated blood purification technology that we believe is not fully reflected in our current
valuation.
“Developed with approximately $16 million
in prior non-dilutive U.S. government funding, HemoDefend-BGA is designed to remove anti-A and anti-B antibodies from plasma and platelet
products, with the goal of enabling universal blood products that can be transfused regardless of recipient blood type - without electricity,
capital equipment, or complex processing.
“The potential implications are substantial.
Rather than maintaining separate plasma and platelet inventories for four blood types, hospitals could potentially simplify inventory
management to just one universal plasma and one universal platelet product, reducing logistical complexity, waste, and costs. Longer term,
the technology could enable first responders, ambulances, and military units to carry freeze-dried universal plasma that requires no refrigeration
or blood typing, allowing faster treatment of life-threatening hemorrhage in emergency and battlefield settings.
“Following helpful FDA feedback in July regarding
our anticipated clinical development pathway, we are evaluating opportunities to advance and realize the value of HemoDefend-BGA through
additional non-dilutive government funding, commercial partnerships, licensing arrangements, and other strategic alternatives. We believe
this asset offers opportunities to create shareholder value without necessarily requiring substantial investment from our core operations.
Concluding Remarks
Dr. Chan concluded, “With operating
cash flow breakeven achieved and a more efficient cost structure in place, CytoSorbents is entering its next phase from a stronger operational
position. Our priorities are clear: sustaining financial discipline, restoring profitable growth in our core CytoSorb franchise, advancing
DrugSorb-ATR toward U.S. commercialization, and unlocking the strategic value of HemoDefend-BGA.
“These four distinct value drivers provide
multiple potential pathways to shareholder value creation, reducing our dependence on any single commercial, regulatory, or strategic
outcome. With improving fundamentals, meaningful near-term catalysts, and substantial longer-term market opportunities, we believe CytoSorbents
is positioned to become a stronger, more profitable, and more diversified medical technology company.”
Explanatory Note
This press release was originally issued on November 12,
2026 and has been updated on November 19, 2026 to reflect revisions to the loss on foreign currency transactions and related amounts
reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the U.S.
Securities and Exchange Commission (“SEC”) on November 19, 2026. As a result, net loss for the third quarter of 2026
is $2.1 million, or $0.65 per share (previously reported as $1.8 million, or $0.58 per share), and net loss for the nine months ended
September 30, 2026 is $12.0 million, or $3.82 per share (previously reported as $11.4 million, or $3.62 per share). Additionally,
this revised press release corrects certain balance sheet and stockholders’ equity (deficit) amounts, general and administrative
expenses and restructuring expenses for the nine months ended September 30, 2026, and certain revenue growth and sales mix percentages
to conform to the Form 10-Q. These revisions are non-cash and do not affect previously reported revenue, gross profit, total operating
expenses, loss from operations, third quarter Adjusted EBITDA, or cash. Other than these updates and the conference call information below,
this press release speaks as of November 12, 2026, and has not been updated for events or information arising after that date.
Third Quarter 2026 Earnings Conference Call
CytoSorbents’ management hosted a live conference
call, presentation webcast, and a question-and-answer session as follows:
| · | Date: Thursday, November 12, 2026 |
An archived recording of the conference call is
available under the Investor Relations section of the Company’s website at https://ir.cytosorbents.com/. An updated version of the
conference call presentation, reflecting the revised financial information described above, has been furnished as an exhibit to the Company’s
Current Report on Form 8-K/A filed with the SEC on November 19, 2026.
About Non-GAAP Financial Measures
To supplement our condensed consolidated financial
statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and
amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense, the gain or loss of foreign exchange translation,
and restructuring charges. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss
Per Share which excludes non-cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges
from Net Loss and Net Loss Per Share, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or
principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may
be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our
financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial
measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for
financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial
measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring
to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe
these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics
used by management in its financial and operational decision-making and (2) they are used by investors and the analyst community
to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability
to meet future capital expenditure and working capital requirements. For a reconciliation of non-GAAP financial measures to the most comparable
GAAP measure, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment
of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary
blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from
blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood
pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO,
and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed,
and then back into the body. CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important
applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2)
the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient
death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine
release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the
removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely
high, and there are few, if any, effective treatments.
CytoSorbents’ lead product, CytoSorb®,
is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to
date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions
were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor
and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United
States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved
or cleared in the United States.
In the U.S. and Canada, CytoSorbents is developing
the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb,
to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough
Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and
rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval
of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb-ATR
is not yet granted or approved in either the U.S. or Canada.
The Company has numerous marketed products and
products under development based upon this unique blood purification technology protected by many issued U.S. and international patents
and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™,
HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, PuriFi®, HotSwap®, and others. For more information,
please visit the Company’s website at https://ir.cytosorbents.com/ or follow us on Facebook and X.
Forward-Looking Statements
This press release includes forward-looking statements
intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations
and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms
such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press
release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially
from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited
to, our restructuring of our direct sales team and strategy in Germany, our ability to successfully obtain U.S. FDA and Health Canada
marketing authorization or approval, our ability to sustain operating cash-flow break-even, our ability to regain and maintain compliance
with Nasdaq continued listing requirements, our ability to appropriately finance the Company, including the extension, refinancing or
repayment of our existing debt, our ability to develop and commercialize our products and product candidates including securing necessary
funding and strategic partnerships, our ability to attract, retain and effectively integrate qualified personnel to support our business
and growth objectives and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal
securities laws.
Please Click to Follow Us on Facebook and X
U.S. Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
ir@cytosorbents.com
CYTOSORBENTS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except share data)
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| | |
(unaudited) | | |
| |
| ASSETS | |
| | | |
| | |
| Current Assets: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 4,205 | | |
$ | 6,249 | |
| Accounts receivable, net of allowances of $416 and $164 as of September 30, 2026 and December 31, 2025, respectively | |
| 7,070 | | |
| 7,550 | |
| Inventories - net | |
| 3,227 | | |
| 5,281 | |
| Prepaid expenses and other current assets | |
| 938 | | |
| 1,554 | |
| Total current assets | |
| 15,440 | | |
| 20,634 | |
| | |
| | | |
| | |
| Property and equipment - net | |
| 6,890 | | |
| 7,823 | |
| Restricted cash | |
| 1,522 | | |
| 1,522 | |
| Right-of-use asset | |
| 10,452 | | |
| 10,924 | |
| Patents - net | |
| 2,804 | | |
| 3,226 | |
| Other assets | |
| 52 | | |
| 53 | |
| Total assets | |
$ | 37,160 | | |
$ | 44,182 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |
| | | |
| | |
| Current Liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 2,775 | | |
$ | 2,869 | |
| Accrued expenses and other current liabilities | |
| 7,120 | | |
| 6,299 | |
| Lease liability – current portion | |
| 614 | | |
| 541 | |
| Current maturities of long-term debt, net of debt discount | |
| 17,523 | | |
| — | |
| Total current liabilities | |
| 28,032 | | |
| 9,709 | |
| Lease liability, net of current portion | |
| 11,437 | | |
| 11,903 | |
| Long-term debt, net of current portion and debt discount | |
| — | | |
| 16,667 | |
| Total liabilities | |
| 39,469 | | |
| 38,279 | |
| | |
| | | |
| | |
| Commitments and Contingencies | |
| | | |
| | |
| | |
| | | |
| | |
| Stockholders’ equity (deficit) | |
| | | |
| | |
| Preferred Stock, par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2026 and December 31, 2025 | |
| — | | |
| — | |
| Common Stock, par value $0.001, 100,000,000 shares authorized; 3,152,889 and 3,140,216 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively (1) | |
| 3 | | |
| 3 | |
| Additional paid-in capital (1) | |
| 322,177 | | |
| 321,084 | |
| Accumulated other comprehensive loss | |
| (277 | ) | |
| (2,977 | ) |
| Accumulated deficit | |
| (324,212 | ) | |
| (312,207 | ) |
| Total stockholders’ equity (deficit) | |
| (2,309 | ) | |
| 5,903 | |
| Total liabilities and stockholders’ equity (deficit) | |
$ | 37,160 | | |
$ | 44,182 | |
(1) Share and per share amounts and the common
stock / additional paid-in capital split have been retroactively adjusted for the 1-for-20 reverse stock split effected September 8,
2026.
See accompanying notes to condensed consolidated
financial statements.
CYTOSORBENTS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)
(in thousands, except share and per share data)
| | |
Three Months
Ended | | |
Three Months
Ended | | |
Nine Months Ended | | |
Nine Months Ended | |
| | |
September 30, 2026 | | |
September 30, 2025 | | |
September 30, 2026 | | |
September 30, 2025 | |
| Revenue, net | |
$ | 9,728 | | |
$ | 9,485 | | |
$ | 28,224 | | |
$ | 27,829 | |
| Cost of goods sold | |
| 2,400 | | |
| 2,819 | | |
| 7,719 | | |
| 8,142 | |
| Gross profit | |
| 7,328 | | |
| 6,666 | | |
| 20,505 | | |
| 19,687 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating expenses | |
| | | |
| | | |
| | | |
| | |
| Research and development, net of grant income | |
| 1,145 | | |
| 918 | | |
| 3,623 | | |
| 3,842 | |
| Selling, general and administrative | |
| 7,102 | | |
| 8,610 | | |
| 23,173 | | |
| 26,209 | |
| Restructuring | |
| 250 | | |
| — | | |
| 562 | | |
| — | |
| Total operating expenses | |
| 8,497 | | |
| 9,528 | | |
| 27,358 | | |
| 30,051 | |
| Loss from operations | |
| (1,169 | ) | |
| (2,862 | ) | |
| (6,853 | ) | |
| (10,364 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Other income (expense) | |
| | | |
| | | |
| | | |
| | |
| Interest expense, net | |
| (892 | ) | |
| (645 | ) | |
| (2,618 | ) | |
| (1,866 | ) |
| Gain (loss) on foreign currency transactions | |
| 7 | | |
| (64 | ) | |
| (2,534 | ) | |
| 9,128 | |
| Total other income (expense), net | |
| (885 | ) | |
| (709 | ) | |
| (5,152 | ) | |
| 7,262 | |
| Loss before benefit from income taxes | |
| (2,054 | ) | |
| (3,571 | ) | |
| (12,005 | ) | |
| (3,102 | ) |
| Benefit from income taxes | |
| — | | |
| 401 | | |
| — | | |
| 401 | |
| Net loss | |
$ | (2,054 | ) | |
$ | (3,170 | ) | |
$ | (12,005 | ) | |
$ | (2,701 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Basic and diluted net loss per common share (1) | |
$ | (0.65 | ) | |
$ | (1.01 | ) | |
$ | (3.82 | ) | |
$ | (0.87 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average shares of common stock outstanding – basic and diluted (1) | |
| 3,146,710 | | |
| 3,137,698 | | |
| 3,141,352 | | |
| 3,101,945 | |
| | |
| | | |
| | | |
| | | |
| | |
| Other comprehensive income (loss): | |
| | | |
| | | |
| | | |
| | |
| Foreign currency translation adjustment, net of tax | |
| 315 | | |
| 116 | | |
| 2,700 | | |
| (8,096 | ) |
| Comprehensive loss | |
$ | (1,739 | ) | |
$ | (3,054 | ) | |
$ | (9,305 | ) | |
$ | (10,797 | ) |
(1) Share and per share amounts for all periods
have been retroactively adjusted to reflect the 1-for-20 reverse stock split effected September 8, 2026.
See accompanying notes to condensed consolidated
financial statements.
CYTOSORBENTS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN STOCKHOLDERS’ EQUITY (DEFICIT)
(UNAUDITED)
(in thousands, except share data)
| | |
Common Stock | | |
Par | | |
Additional
Paid-In | | |
Accumulated Other
Comprehensive | | |
Accumulated | | |
Total
Stockholders’ | |
| | |
Shares | | |
Value | | |
Capital | | |
Loss | | |
Deficit | | |
Equity (Deficit) | |
| For the three months ended September 30, 2026 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Balance as of June 30, 2026 (unaudited) (1) | |
| 3,142,139 | | |
$ | 3 | | |
$ | 321,996 | | |
$ | (592 | ) | |
$ | (322,158 | ) | |
$ | (751 | ) |
| Stock-based compensation | |
| — | | |
| — | | |
| 291 | | |
| — | | |
| — | | |
| 291 | |
| Common stock issued upon vesting of restricted stock units, less shares withheld to cover taxes | |
| 8,964 | | |
| — | | |
| (110 | ) | |
| — | | |
| — | | |
| (110 | ) |
| Rounding of fractional shares in reverse stock split | |
| 1,786 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| Foreign translation adjustment | |
| — | | |
| — | | |
| — | | |
| 315 | | |
| — | | |
| 315 | |
| Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| (2,054 | ) | |
| (2,054 | ) |
| Balance as of September 30, 2026 (unaudited) | |
| 3,152,889 | | |
$ | 3 | | |
$ | 322,177 | | |
$ | (277 | ) | |
$ | (324,212 | ) | |
$ | (2,309 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| For the nine months ended September 30, 2026 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Balance as of December 31, 2025 | |
| 3,140,216 | | |
$ | 3 | | |
$ | 321,084 | | |
$ | (2,977 | ) | |
$ | (312,207 | ) | |
$ | 5,903 | |
| Stock-based compensation | |
| — | | |
| — | | |
| 1,203 | | |
| — | | |
| — | | |
| 1,203 | |
| Reversal of excess RSU shares issued | |
| (3,550 | ) | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| Rounding of fractional shares in reverse stock split | |
| 1,786 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| Common stock issued upon vesting of restricted stock units, less shares withheld to cover taxes | |
| 14,437 | | |
| — | | |
| (110 | ) | |
| — | | |
| — | | |
| (110 | ) |
| Foreign translation adjustment | |
| — | | |
| — | | |
| — | | |
| 2,700 | | |
| — | | |
| 2,700 | |
| Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| (12,005 | ) | |
| (12,005 | ) |
| Balance as of September 30, 2026 (unaudited) | |
| 3,152,889 | | |
$ | 3 | | |
$ | 322,177 | | |
$ | (277 | ) | |
$ | (324,212 | ) | |
$ | (2,309 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| For the three months ended September 30, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Balance as of June 30, 2025 (unaudited) | |
| 3,130,519 | | |
$ | 3 | | |
$ | 319,083 | | |
$ | (3,960 | ) | |
$ | (303,540 | ) | |
$ | 11,586 | |
| Stock-based compensation | |
| — | | |
| — | | |
| 488 | | |
| — | | |
| — | | |
| 488 | |
| Common stock issued upon vesting of restricted stock units, less shares withheld to cover taxes | |
| 9,196 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| Foreign currency translation adjustment, net of tax | |
| — | | |
| — | | |
| — | | |
| 116 | | |
| — | | |
| 116 | |
| Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| (3,170 | ) | |
| (3,170 | ) |
| Balance as of September 30, 2025 (unaudited) | |
| 3,139,715 | | |
$ | 3 | | |
$ | 319,571 | | |
$ | (3,844 | ) | |
$ | (306,710 | ) | |
$ | 9,020 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| For the nine months ended September 30, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Balance as of December 31, 2024 | |
| 2,741,507 | | |
$ | 3 | | |
$ | 310,861 | | |
$ | 4,252 | | |
$ | (304,009 | ) | |
$ | 11,107 | |
| Stock-based compensation | |
| — | | |
| — | | |
| 1,879 | | |
| — | | |
| — | | |
| 1,879 | |
| Common stock issued upon vesting of restricted stock units, less shares withheld to cover taxes | |
| 14,858 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| Issuance of common stock and warrants from rights offerings, net of fees incurred | |
| 312,490 | | |
| — | | |
| 5,392 | | |
| — | | |
| — | | |
| 5,392 | |
| Issuance of common stock from exercise of warrants | |
| 70,860 | | |
| — | | |
| 1,439 | | |
| — | | |
| — | | |
| 1,439 | |
| Foreign translation adjustment | |
| — | | |
| — | | |
| — | | |
| (8,096 | ) | |
| — | | |
| (8,096 | ) |
| Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| (2,701 | ) | |
| (2,701 | ) |
| Balance as of September 30, 2025 (unaudited) | |
| 3,139,715 | | |
$ | 3 | | |
$ | 319,571 | | |
$ | (3,844 | ) | |
$ | (306,710 | ) | |
$ | 9,020 | |
(1) Balances as of June 30, 2026 have
been revised to correct immaterial errors in the foreign currency transaction loss previously recognized on the remeasurement of a euro-denominated
intercompany balance. See Note 12, Revision of Previously Issued Interim Financial Statements, in the Company’s Quarterly Report
on Form 10-Q for the quarter ended September 30, 2026.
CYTOSORBENTS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands)
| | |
Nine Months Ended | | |
Nine Months Ended | |
| | |
September 30, 2026 | | |
September 30, 2025 | |
| Cash flows from operating activities | |
| | | |
| | |
| Net loss | |
$ | (12,005 | ) | |
$ | (2,701 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
| Amortization of debt discount | |
| 856 | | |
| 571 | |
| Amortization of patents | |
| 192 | | |
| 198 | |
| Depreciation and amortization | |
| 851 | | |
| 939 | |
| Amortization of right-of-use asset | |
| 79 | | |
| 109 | |
| Loss on abandoned patents | |
| 338 | | |
| 176 | |
| Write-off of inventory | |
| — | | |
| 253 | |
| Bad debt expense | |
| 255 | | |
| 17 | |
| Stock-based compensation | |
| 1,203 | | |
| 1,879 | |
| Foreign currency transaction (gains) losses | |
| 2,534 | | |
| (9,128 | ) |
| Changes in operating assets and liabilities | |
| | | |
| | |
| Accounts receivable | |
| 51 | | |
| 560 | |
| Inventories | |
| 1,996 | | |
| (1,247 | ) |
| Prepaid expenses and other current assets | |
| 694 | | |
| 989 | |
| Other assets | |
| 1 | | |
| — | |
| Accounts payable and accrued expenses | |
| 943 | | |
| (167 | ) |
| Net cash used in operating activities | |
| (2,012 | ) | |
| (7,552 | ) |
| | |
| | | |
| | |
| Cash flows from investing activities | |
| | | |
| | |
| Purchases of property and equipment | |
| (45 | ) | |
| (56 | ) |
| Disposals of property and equipment | |
| 110 | | |
| — | |
| Payments for patent costs | |
| (108 | ) | |
| (68 | ) |
| Net cash used in investing activities | |
| (43 | ) | |
| (124 | ) |
| | |
| | | |
| | |
| Cash flows from financing activities | |
| | | |
| | |
| Proceeds from exercise of common stock warrants | |
| — | | |
| 1,439 | |
| Proceeds from rights offering, net | |
| — | | |
| 5,392 | |
| Net cash provided by financing activities | |
| — | | |
| 6,831 | |
| | |
| | | |
| | |
| Effect of exchange rates on cash | |
| 11 | | |
| 139 | |
| Net change in cash, cash equivalents, and restricted cash | |
| (2,044 | ) | |
| (706 | ) |
| Cash, cash equivalents, and restricted cash as of beginning of period | |
| 7,771 | | |
| 9,764 | |
| Cash, cash equivalents, and restricted cash as of end of period | |
$ | 5,727 | | |
$ | 9,058 | |
| | |
| | | |
| | |
| Supplemental disclosure of cash flow information | |
| | | |
| | |
| Cash paid for interest | |
$ | 1,806 | | |
$ | 1,535 | |
RECONCILIATION OF GAAP FINANCIAL MEASURES TO
NON-GAAP FINANCIAL MEASURES
(amounts in thousands, except share and per
share data)
| | |
Three Months Ended | | |
Three Months Ended | | |
Nine Months Ended | | |
Nine Months Ended | |
| | |
September 30, 2026 | | |
September 30, 2025 | | |
September 30, 2026 | | |
September 30, 2025 | |
| Net loss | |
$ | (2,054 | ) | |
$ | (3,170 | ) | |
$ | (12,005 | ) | |
$ | (2,701 | ) |
| Depreciation and amortization expense | |
| 344 | | |
| 364 | | |
| 1,043 | | |
| 1,137 | |
| Income tax expense (benefit) | |
| — | | |
| (401 | ) | |
| — | | |
| (401 | ) |
| Interest expense, net | |
| 892 | | |
| 645 | | |
| 2,618 | | |
| 1,866 | |
| EBITDA – non-GAAP measure | |
$ | (818 | ) | |
$ | (2,562 | ) | |
$ | (8,344 | ) | |
$ | (99 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Non-cash stock-based compensation expense | |
| 291 | | |
| 488 | | |
| 1,203 | | |
| 1,879 | |
| (Gain)/Loss on foreign currency transactions | |
| (7 | ) | |
| 64 | | |
| 2,534 | | |
| (9,128 | ) |
| Restructuring | |
| 250 | | |
| — | | |
| 562 | | |
| — | |
| Adjusted EBITDA – non-GAAP measure | |
$ | (284 | ) | |
$ | (2,010 | ) | |
$ | (4,045 | ) | |
$ | (7,348 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss | |
$ | (2,054 | ) | |
$ | (3,170 | ) | |
$ | (12,005 | ) | |
$ | (2,701 | ) |
| Non-cash stock-based compensation expense | |
| 291 | | |
| 488 | | |
| 1,203 | | |
| 1,879 | |
| (Gain)/Loss on foreign currency transactions | |
| (7 | ) | |
| 64 | | |
| 2,534 | | |
| (9,128 | ) |
| Restructuring | |
| 250 | | |
| — | | |
| 562 | | |
| — | |
| Adjusted net loss – non-GAAP measure | |
$ | (1,520 | ) | |
$ | (2,618 | ) | |
$ | (7,706 | ) | |
$ | (9,950 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average common shares outstanding – basic and diluted (1) | |
| 3,146,710 | | |
| 3,137,698 | | |
| 3,141,352 | | |
| 3,101,945 | |
| Basic and diluted net loss per common share | |
$ | (0.65 | ) | |
$ | (1.01 | ) | |
$ | (3.82 | ) | |
$ | (0.87 | ) |
| Non-cash stock-based compensation expense per share | |
$ | 0.09 | | |
$ | 0.16 | | |
$ | 0.38 | | |
$ | 0.61 | |
| (Gain)/Loss on foreign currency transactions per share | |
$ | (0.00 | ) | |
$ | 0.02 | | |
$ | 0.81 | | |
$ | (2.94 | ) |
| Restructuring per share | |
$ | 0.08 | | |
$ | — | | |
$ | 0.18 | | |
$ | — | |
| Adjusted net loss per common share – basic and diluted – non-GAAP measure | |
$ | (0.48 | ) | |
$ | (0.83 | ) | |
$ | (2.45 | ) | |
$ | (3.21 | ) |
(1) Share and per share amounts for all periods
have been retroactively adjusted to reflect the 1-for-20 reverse stock split effected September 8, 2026.
Exhibit 99.2

CytoSorbents Corporation Nasdaq: CTSO Q3 2026 Earnings Conference Call November 12, 2026 (Updated November 19, 2026 – see Explanatory Note)

This presentation was originally used in connection with the CytoSorbents Corporation third quarter 2026 earnings conference call held on November 12 , 2026 . It has been updated, and is being furnished as an exhibit to the Company’s Current Report on Form 8 - K/A filed with the U . S . Securities and Exchange Commission (“SEC”) on November 19 , 2026 , to reflect revisions to the loss on foreign currency transactions and related amounts reported in the Company’s Quarterly Report on Form 10 - Q for the quarter ended September 30 , 2026 , filed with the SEC on the same date . The updated press release is also included in the Form 8 - K/A . Updated amounts appear on slides 10 , 11 and 24 . Third quarter 2026 net loss is $ 2 . 1 million (previously $ 1 . 8 million) and nine - month 2026 net loss is $ 12 . 0 million (previously $ 11 . 4 million), with related changes to EBITDA and to the reconciliation of non - GAAP financial measures . Growth in direct sales outside Germany has also been conformed to 5 % (previously 4 % ) on slides 9 , 14 and 21 . These revisions are non - cash and do not affect previously reported revenue, gross profit, operating expenses, loss from operations, third quarter Adjusted EBITDA, or cash . Except as described above, this presentation speaks as of November 12 , 2026 , and the Company has not updated it for events or information arising after that date . Explanatory Note 2

Conference Call Participants Phillip Chan, MD, PhD Chief Executive Officer Peter J. Mariani, CPA Chief Financial Officer 3

Statements in this presentation include forward - looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995 . These forward - looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward - looking statements are expressed differently . You should be aware that the forward - looking statements in this presentation represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward - looking statements . Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, our ability to successfully obtain U . S . FDA and Health Canada marketing authorization or approval, our ability to sustain operating cash - flow break - even, our ability to regain and maintain compliance with Nasdaq continued listing requirements, our ability to appropriately finance the Company, including the extension, refinancing or repayment of our existing debt, our ability to develop and commercialize our products and product candidates including securing necessary funding and strategic partnerships, our ability to attract, retain and effectively integrate qualified personnel to support our business and growth objectives, and the risks discussed in our Annual Report on Form 10 - K, filed with the SEC on March 30 , 2026 , as updated by the risks reported in our Quarterly Reports on Form 10 - Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business . We caution you not to place undue reliance upon any such forward - looking statements . We undertake no obligation to publicly update or revise any forward - looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws . Safe Harbor Statement 4 About Non - GAAP Financial Measures To supplement our condensed consolidated financial statements, we use the non - GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non - cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges . We also use the non - GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Share which excludes non - cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges from Net Loss and Net Loss Per Share, respectively . Additionally, we use the non - GAAP financial measure of Negative Free Cash Flow which consists of net cash used in operating activities plus net cash used in investing activities . These non - GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non - GAAP measures used by other companies . In addition, these non - GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP . The reconciliations of the non - GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated . We use these non - GAAP financial measures for financial and operational decision - making and as a means to evaluate period - to - period comparisons . We believe that these non - GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non - GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods . We believe these non - GAAP financial measures are useful to investors because ( 1 ) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision - making and ( 2 ) they are used by investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements . For a reconciliation of non - GAAP financial measures to the most comparable GAAP measure, see the reconciliation included in the financial tables . All non - GAAP adjustments are presented pre - tax .

Operational Update Dr. Phillip Chan, MD, PhD Chief Executive Officer 5

75% Gross Margin Achieved operating cash flow breakeven, the first of four distinct value drivers • Gross margin expanded to 75%, up from 73% in Q2 2026 and 70% in Q3 2025 • Operating expenses down 11%; adjusted EBITDA loss narrowed 86% • Year - to - date cash used in operations down 73% to $2.0M • Advancing DrugSorb - ATR toward a new De Novo submission in early 2027 $9.7M Q3 2026 Revenue +$43K Operating Cash Flow* * Excluding ~$251K of restructuring - related payments. Q3 2026: A Financial Milestone 6

Four Distinct Drivers of Value Creation 7 ✓ Achieved

Financial Highlights and Value Driver #1 Achieved Operating Cash Flow Breakeven Peter J. Mariani Chief Financial Officer | 8 ✓ Achieved

YoY Change Q3 2026 +3% $9.7m Revenue: +18% $5.1m Distributors and Strategic Partners +5% $2.4m Direct Intl - 21% $2.3m Germany • Growth led by distributor and strategic partner sales, up 18 % year - over - year • Direct sales outside Germany up 5 % year - over - year • Germany down 21 % , reflecting reduced territory coverage after our commercial restructuring ; sales team being rebuilt • Revenue up 1 % sequentially from Q 2 2026 | 9 Q3 2026 Revenue

Q3 2026 Performance Margin expansion and cost discipline cut adjusted EBITDA loss 86% | 10 Revenue $9.7M ▲ 3% vs. $9.5M in Q3 2025 Gross margin 75% ▲ 5 pts vs. 70% in Q3 2025 Operating expenses $8.5M ▼ 11% vs. $9.5M in Q3 2025 Operating loss ($1.2M) 59% improvement vs. ($2.9M) in Q3 2025 Net loss ($2.1M) 35% improvement vs. ($3.2M) in Q3 2025 Adjusted EBITDA loss* ($0.3M) 86% improvement vs. ($2.0M) in Q3 2025 Adjusted EBITDA loss by quarter* 2026, $ millions ($2.1M) ($1.6M) ($0.3M) Q1 2026 Q2 2026 Q3 2026 Improved every quarter of 2026 * Non - GAAP measure; see the reconciliation in the appendix. Quarterly figures rounded .

9 - month 2026 Performance Adjusted EBITDA loss improved 45% on higher margins and lower costs | 11 Revenue $28.2M ▲ 1% vs. $27.8M in 9M 2025 Gross margin 73% ▲ 2 pts vs. 71% in 9M 2025 Operating expenses $27.4M ▼ 9% vs. $30.1M in 9M 2025 Operating loss ($6.9M) 34% improvement vs. ($10.4M) in 9M 2025 Net loss ($12.0M) Reflects FX swing vs. ($2.7M) in 9M 2025 Adjusted EBITDA loss* ($4.0M) 45% improvement vs. ($7.3M) in 9M 2025 Operating loss improved 34% $3.5M better: ($6.9M) vs. ($10.4M) Key drivers (favorable impact) Higher gross profit (72.7% margin) +$0.8M Lower selling, travel and marketing +$1.1M Lower compensation (workforce plan) +$1.0M Lower legal, financial and consulting +$0.8M Lower R&D, including clinical studies +$0.2M Partly offset by $0.6M of restructuring charges * Non - GAAP measure; see the reconciliation in the appendix. Net loss includes an $11.7M swing in non - cash foreign currency ($2.5 M loss in 9M 2026 vs. $9.1M gain in 9M 2025).

• +$43K operating cash flow in Q3, excluding ~$251K of restructuring - related payments • Total Q3 cash burn of ~$0.2M; $5.7M of cash, cash equivalents and restricted cash at September 30 • Year - to - date cash used in operations down 73% to $2.0M • Focus now shifts to remaining at or near breakeven; quarterly results may fluctuate with timing of revenue, collections and working capital • Actively working to satisfy the remaining Nasdaq listing requirement and debt restructuring by the end of this year Operating Cash Flow Breakeven Achieved in Q3 2026 * Negative Free Cash Flow = Net cash used in operating activities plus net cash used in investing activities ($7,000) ($6,000) ($5,000) ($4,000) ($3,000) ($2,000) ($1,000) $0 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Amount ($ thousands) Negative Free Cash Flow by Quarter (Q3 2023 - Q3 2026) Fundamental improvements drive breakeven | 12

Value Driver #2: Driving Core CytoSorb Sales Growth Dr. Phillip Chan, MD, PhD Chief Executive Officer 13 CytoSorb is approved in the EU but is not yet cleared or approved i n the U.S. and Canada

+5% Direct Intl Growing markets are 77% of sales; restoring growth in Germany is a top priority • Two new German sales representatives added; one more next month and two more by early 2027 • Alex Tiefenbacher joined as SVP of Direct Sales (C.R. Bard, Becton Dickinson, GE Healthcare, Baxter) • “Right Patient, Right Time, Right Dose” strategy gaining traction with PuriFi® and HotSwap® • Expanding clinical evidence, including EACTS 2026 and COSMOS registry data at ESICM LIVES 2026 +1 8 % Distributors* - 2 1 % Germany * Distributor and strategic partner sales. All growth rates are Q3 2026 vs. Q3 2025 . Returning CytoSorb to Growth 14

Value Driver #3: Opening the U.S. Market Through DrugSorb - ATR Dr. Phillip Chan, MD, PhD Chief Executive Officer 15 DrugSorb - ATR is an investigational device in th e U.S. and Canada and not yet cleared/approved

~8 NNT** Two distinct potential pathways to U.S. commercialization • Brilinta® (ticagrelor): new De Novo submission planned for early 2027, with ~5x more treated patients • ESC data also showed less chest tube drainage and fewer transfusions, with no serious device - related AEs • After a constructive August pre - sub, finalizing an animal study protocol with FDA for mechanistic data • DOACs (Eliquis®, Xarelto®): separate De Novo submission expected in 2027 • Initial U.S. and Canada market of ~$300M, expandable to $1 – 2B with label expansion 37% Less Bleeding* ~250 Patients in Submission * Severe (BARC - 4) bleeding, 21.8% vs. 34.5% (p=0.002); 587 urgent CABG patients, ESC 2026. ** Number needed to treat. DrugSorb - ATR is investigational in the U.S. and Canada and not yet cleared/approved. DrugSorb - ATR: Path to Approval 16

Dr. Phillip Chan, MD, PhD Chief Executive Officer Value Driver #4: Unlocking the Strategic Value of HemoDefend - BGA | 17

HemoDefend - BGA: Unlocking Strategic Value • Simple, gravity - driven filter that removes anti - A and anti - B antibodies to enable universal plasma and platelets • No electricity, capital equipment or complex processing required • Could simplify blood bank inventories to one universal plasma and one universal platelet product • Longer term, could enable freeze - dried universal plasma for first responders and the military, with no refrigeration or blood typing • Developed with ~$16M of prior non - dilutive U.S. government funding • Constructive FDA feedback on our anticipated clinical pathway in July 2026 • Pursuing non - dilutive funding, commercial partnerships, licensing and other strategic alternatives Potential to unlock shareholder value without substantial investment from our core operations | 18

Closing Remarks Phillip Chan, MD, PhD Chief Executive Officer | 19

Four Distinct Value Drivers. One Uncommon Value | 20 ✓ Achieved

Value Driver Scorecard | 21 What's Next Q3 2026 Progress Value Driver Sustain at or near breakeven; selectively invest in sales growth ✓ Achieved: +$43K operating cash flow*; adjusted EBITDA loss down 86% 1. Operating Cash Flow Breakeven Rebuild German sales force (5 new reps by early 2027) under new SVP of Direct Sales Distributors +18%, Direct Intl +5% (together 77% of sales); Germany −21% 2. Core CytoSorb Sales Growth Brilinta® De Novo in early 2027; separate DOAC De Novo in 2027 ESC 2026: 37% less severe bleeding in 587 urgent CABG patients; constructive FDA pre - subs 3. U.S. Market with DrugSorb - ATR Pursue non - dilutive funding, partnerships, licensing and other alternatives Constructive FDA feedback on clinical pathway (July 2026) 4. Strategic Value of HemoDefend - BGA * Excluding ~$251K of restructuring - related payments. Growth rates are Q3 2026 vs. Q3 2025. DrugSorb - ATR is investigational in t he U.S. and Canada and not yet cleared/approved.

Company Contacts: Dr. Phillip Chan - CEO pchan@cytosorbents.com Peter Mariani – CFO pmariani@cytosorbents.com Q&A Session NASDAQ: CTSO 22

Appendix Reconciliation of non - GAAP Financial Measures | 23

Reconciliation of Non - GAAP Financial Measures | 24 9M 2025 9M 2026 Q3 2025 Q3 2026 ($ thousands, except per share) (2,701) (12,005) (3,170) (2,054) Net loss 1,137 1,043 364 344 Depreciation and amortization (401) — (401) — Income tax benefit 1,866 2,618 645 892 Interest expense, net (99) (8,344) (2,562) (818) EBITDA 1,879 1,203 488 291 Non - cash stock - based compensation (9,128) 2,534 64 (7) (Gain) loss on foreign currency transactions — 562 — 250 Restructuring (7,348) (4,045) (2,010) (284) Adjusted EBITDA (2,701) (12,005) (3,170) (2,054) Net loss 1,879 1,203 488 291 Non - cash stock - based compensation (9,128) 2,534 64 (7) (Gain) loss on foreign currency transactions — 562 — 250 Restructuring (9,950) (7,706) (2,618) (1,520) Adjusted net loss ($3.21) ($2.45) ($0.83) ($0.48) Adjusted net loss per share